CovidChloroV1, Main, Corpus, bibRecord, 000432

Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.

Identifieur interne : 000432 ( Main/Corpus ); précédent : 000431; suivant : 000433

Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.

Source :

Tzu chi medical journal [ 2223-8956 ]

RBID : pubmed:33505872

Abstract

So far, lots of analyses have been conducted to invent the appropriate therapeutic targets for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The category and the strategies for treating the virus are described in this review together with mentioning some specific drugs. Of them, saikosaponin possesses affinity of the drug toward nonstructural protein 15 and the spike glycoprotein of the SARS-CoV-2. The nucleotide inhibitors such as sofosbuvir, ribavirin, galidesivir, remdesivir, favipiravir, cefuroxime, tenofovir, and hydroxychloroquine (HCHL), setrobuvir, YAK, and IDX-184 were found to be effective in binding to SARS-CoV-2 RNA-dependent RNA polymerase. From the antimalarial and anti-inflammatory category, chloroquine and its derivative HCHL have already been approved by the U.S. Food and Drug Administration for emergency treatment of SARS-CoV-2 infection. The other drugs such as favipiravir and lopinavir/ritonavir under the antiviral category, the angiotensin-converting enzyme 2 (the renin-angiotensin system inhibitors), remdesivir (RNA polymerase inhibitor) from antiviral category, cepharanthine from anti-inflammatory category, etc., have been pointed based on the previous literature published. Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation.

DOI: 10.4103/tcmj.tcmj_100_20
PubMed: 33505872
PubMed Central: PMC7821824

Links to Exploration step

pubmed:33505872

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.</title>
<author><name sortKey="Noor, Rashed" sort="Noor, Rashed" uniqKey="Noor R" first="Rashed" last="Noor">Rashed Noor</name>
<affiliation><nlm:affiliation>Department of Microbiology, School of Life Sciences, Independent University Bangladesh, Dhaka, Bangladesh.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021 Jan-Mar</date>
<idno type="RBID">pubmed:33505872</idno>
<idno type="pmid">33505872</idno>
<idno type="doi">10.4103/tcmj.tcmj_100_20</idno>
<idno type="pmc">PMC7821824</idno>
<idno type="wicri:Area/Main/Corpus">000432</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000432</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.</title>
<author><name sortKey="Noor, Rashed" sort="Noor, Rashed" uniqKey="Noor R" first="Rashed" last="Noor">Rashed Noor</name>
<affiliation><nlm:affiliation>Department of Microbiology, School of Life Sciences, Independent University Bangladesh, Dhaka, Bangladesh.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Tzu chi medical journal</title>
<idno type="eISSN">2223-8956</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">So far, lots of analyses have been conducted to invent the appropriate therapeutic targets for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The category and the strategies for treating the virus are described in this review together with mentioning some specific drugs. Of them, saikosaponin possesses affinity of the drug toward nonstructural protein 15 and the spike glycoprotein of the SARS-CoV-2. The nucleotide inhibitors such as sofosbuvir, ribavirin, galidesivir, remdesivir, favipiravir, cefuroxime, tenofovir, and hydroxychloroquine (HCHL), setrobuvir, YAK, and IDX-184 were found to be effective in binding to SARS-CoV-2 RNA-dependent RNA polymerase. From the antimalarial and anti-inflammatory category, chloroquine and its derivative HCHL have already been approved by the U.S. Food and Drug Administration for emergency treatment of SARS-CoV-2 infection. The other drugs such as favipiravir and lopinavir/ritonavir under the antiviral category, the angiotensin-converting enzyme 2 (the renin-angiotensin system inhibitors), remdesivir (RNA polymerase inhibitor) from antiviral category, cepharanthine from anti-inflammatory category, etc., have been pointed based on the previous literature published. Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33505872</PMID>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2223-8956</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>1</Issue>
<PubDate><MedlineDate>2021 Jan-Mar</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Tzu chi medical journal</Title>
<ISOAbbreviation>Tzu Chi Med J</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.</ArticleTitle>
<Pagination><MedlinePgn>7-12</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/tcmj.tcmj_100_20</ELocationID>
<Abstract><AbstractText>So far, lots of analyses have been conducted to invent the appropriate therapeutic targets for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The category and the strategies for treating the virus are described in this review together with mentioning some specific drugs. Of them, saikosaponin possesses affinity of the drug toward nonstructural protein 15 and the spike glycoprotein of the SARS-CoV-2. The nucleotide inhibitors such as sofosbuvir, ribavirin, galidesivir, remdesivir, favipiravir, cefuroxime, tenofovir, and hydroxychloroquine (HCHL), setrobuvir, YAK, and IDX-184 were found to be effective in binding to SARS-CoV-2 RNA-dependent RNA polymerase. From the antimalarial and anti-inflammatory category, chloroquine and its derivative HCHL have already been approved by the U.S. Food and Drug Administration for emergency treatment of SARS-CoV-2 infection. The other drugs such as favipiravir and lopinavir/ritonavir under the antiviral category, the angiotensin-converting enzyme 2 (the renin-angiotensin system inhibitors), remdesivir (RNA polymerase inhibitor) from antiviral category, cepharanthine from anti-inflammatory category, etc., have been pointed based on the previous literature published. Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation.</AbstractText>
<CopyrightInformation>Copyright: © 2020 Tzu Chi Medical Journal.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noor</LastName>
<ForeName>Rashed</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, School of Life Sciences, Independent University Bangladesh, Dhaka, Bangladesh.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>India</Country>
<MedlineTA>Tzu Chi Med J</MedlineTA>
<NlmUniqueID>101770275</NlmUniqueID>
<ISSNLinking>1016-3190</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drugs</Keyword>
<Keyword MajorTopicYN="N">Therapeutic targets</Keyword>
<Keyword MajorTopicYN="N">Viral mitigation</Keyword>
<Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2 infection</Keyword>
</KeywordList>
<CoiStatement>There are no conflicts of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>28</Day>
<Hour>5</Hour>
<Minute>43</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33505872</ArticleId>
<ArticleId IdType="doi">10.4103/tcmj.tcmj_100_20</ArticleId>
<ArticleId IdType="pii">TCMJ-33-7</ArticleId>
<ArticleId IdType="pmc">PMC7821824</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):64-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32037389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intern Emerg Med. 2020 Nov;15(8):1577-1578</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32347443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 May 6;:1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32338164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):368-370</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2009 Jul;5(7):e1000511</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19593379</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine Growth Factor Rev. 2020 Jun;53:25-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32446778</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Pharm Sin B. 2020 May;10(5):766-788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32292689</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Med. 2020 Mar 12;2(3):354-358</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32292904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Pharm Sci. 2020;23(1):58-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32201449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 May 13;:1-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32345124</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jun;156:104761</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1051-1056</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32149769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Engineering (Beijing). 2020 Oct;6(10):1192-1198</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Virol. 2016 Sep 29;3(1):237-261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27578435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>F1000Res. 2020 Jan 31;9:72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32117569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2020 Apr 10;295(15):4773-4779</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Innate Immun. 2020;12(1):4-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31610541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2020 May - Jun;22(4-5):154-156</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dis. 2020 Dec;7(4):542-550</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32363223</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Aug 10;25(32):6070-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17629360</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2020 May;214:108393</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):189-190</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32071427</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000432 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000432 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33505872
   |texte=   Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33505872" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.

Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki